- Report
- December 2025
- 200 Pages
Global
From €7166EUR$7,950USD£6,157GBP
- Report
- August 2025
- 187 Pages
Global
From €3196EUR$3,545USD£2,746GBP
€3551EUR$3,939USD£3,051GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1803EUR$2,000USD£1,549GBP
- Report
- February 2024
- 180 Pages
Global
From €4479EUR$4,969USD£3,848GBP
- Report
- May 2024
- 136 Pages
Global
From €2703EUR$2,999USD£2,323GBP
€3605EUR$3,999USD£3,097GBP
- Report
- August 2024
- 104 Pages
Global
From €3500EUR$4,159USD£3,112GBP
The GABA Receptor Agonist market is a subset of the Central Nervous System Drugs market. GABA Receptor Agonists are drugs that activate the GABA receptor, a type of neurotransmitter receptor found in the brain. These drugs are used to treat a variety of neurological disorders, including anxiety, insomnia, and epilepsy. GABA Receptor Agonists are typically administered orally, intravenously, or intramuscularly.
The GABA Receptor Agonist market is highly competitive, with a number of large pharmaceutical companies vying for market share. Companies in this market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Additionally, there are a number of smaller companies that specialize in the development and manufacture of GABA Receptor Agonists. Show Less Read more
